Advice
Recommended for use within NHS Scotland.
RECOMMENDATION
FemSeven Conti® offers an alternative continuous combined hormone replacement therapy (HRT) for the treatment of oestrogen deficiency symptoms in postmenopausal women more than one year after menopause. It is formulated as a transdermal patch and is the first continuous combined HRT patch to allow once weekly application. It is not licensed for prophylaxis of osteoporosis.
HRT patches are in general more expensive than oral preparations.
Download detailed advice17KB (PDF)
Medicine details
- Medicine name:
- Estradiol & levonorgestrel patches (FemSeven Conti®)
- SMC ID:
- 28/02
- Indication:
- Hormone replacement therapy for oestrogen deficiency symptoms in post-menopausal women more than one year after menopause.
- Pharmaceutical company
- Merck Serono Ltd
- BNF chapter
- Endocrine system
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 10 January 2003